11-β-Prostaglandin F2α

Some reactions leave no neat allergy-panel answer. If you get episodes of flushing, hives, a racing heart, wheezing, or near-fainting, this test can add a urine signal of mast-cell activation. It is a specialist marker used as a supportive flag. Its accuracy as a standalone mast-cell test is not established, so it does not diagnose mast-cell disease by itself.

Mast cells are immune cells that release chemical signals during allergic reactions and some inflammatory flares. Prostaglandin D2 is one of those signals. It disappears quickly, so labs measure more stable breakdown products in urine.

What This Test Measures

The analyte here is 2,3-dinor-11β-PGF2α in urine. Labs usually adjust it for how concentrated the urine is. It is a downstream product of 11β-PGF2α, also written 9α,11β-PGF2, which comes from prostaglandin D2.

That distinction matters when you read the research. Older mast-cell and asthma studies often measured urinary 11β-PGF2α or 9α,11β-PGF2. Those are related PGD2 metabolites. They are not exactly this test. Newer studies and clinical labs often use the 2,3-dinor form because it separates more cleanly from look-alike molecules.

Mast Cell Activation and Mastocytosis

This marker is most useful when a flare sample can be compared with your own baseline. In a Mayo Clinic review of mast-cell activation episodes confirmed by paired tryptase rises, urinary 2,3-dinor-11β-PGF2α rose during attacks, by about sevenfold on average. In that same series, urinary leukotriene E4 rose even more, so this marker is one of several worth checking together.

Systemic mastocytosis is a disease where abnormal mast cells build up in tissues. Older mastocytosis work measured urinary 11β-PGF2α, a related PGD2 metabolite. In 90 people with mastocytosis, that marker moved with serum tryptase and bone marrow mast-cell burden. Tryptase is a blood marker used in mast-cell disorders.

KIT D816V is a gene change common in systemic mastocytosis. In the same 90-person study, urinary 11β-PGF2α did not separate people with that variant from those without it. Urinary N-methylhistamine did. So this test can support a mast-cell workup, but it does not tell you the genetic subtype.

A high or rising result points toward mediator release and is worth confirming with the rest of the clinical picture. It is a flag, not a diagnosis. Positive and negative predictive values for this urinary marker have not been established, so tryptase, with its rise of 20 percent plus 2 ng/mL during a flare, remains the most accepted mast-cell biomarker, with urinary mediators as emerging adjuncts.

Aspirin-Exacerbated Respiratory Disease

Some people with asthma react badly to aspirin and similar drugs. The pattern is called aspirin-exacerbated respiratory disease. In a challenge study, eight aspirin-intolerant asthmatics had higher urinary 9α,11β-PGF2 after inhaled aspirin, and higher aspirin doses caused larger rises.

That study measured a related PGD2 metabolite rather than 2,3-dinor-11β-PGF2α. The finding still matters because the same people did not show a rise when histamine narrowed their airways. The marker was tracking the mast-cell PGD2 pathway, not just tight airways.

Type 2 Asthma and Flares

Newer evidence for this exact analyte comes from severe asthma. In U-BIOPRED, 597 adults had urine mediator testing. Urinary 2,3-dinor-11β-PGF2α and another PGD2 metabolite were higher in severe asthma than in healthy controls and rose with type 2 inflammation.

Type 2 inflammation is the allergic immune pattern behind many eosinophilic asthma flares. Eosinophils are immune cells often involved in allergic asthma. In that study, higher PGD2 metabolites went with worse lung function and other type 2 signals.

In children, older work measured urinary 9α,11β-PGF2. In a 58-child study, levels rose after exercise challenge in children with exercise-induced asthma and tracked symptom scores during acute attacks. Since this was the older related metabolite, treat exercise-provoked results as supportive evidence, not a standalone answer.

Why a Single Resting Result Can Miss It

Baseline urine levels can overlap between healthy people and people with asthma or mast-cell disease. A quiet-day sample can miss a disease that flares in bursts.

Steroids are less simple than they look. An older urinary 9α,11β-PGF2 study found lower values in people using inhaled corticosteroids, but U-BIOPRED did not find a clear oral-steroid effect on 2,3-dinor-11β-PGF2α. Do not explain away a low value by steroids automatically. Record the medication, then read the result against symptoms and companion markers.

When the Number Can Fool You

• Wrong analyte: 11β-PGF2α, 2,3-dinor-11β-PGF2α, tetranor PGDM, and 8-iso-PGF2α are different molecules. Check the exact name before comparing studies or past labs.
• Aspirin and NSAIDs: regular use can lower 2,3-dinor-11β-PGF2α by blocking prostaglandin production. In aspirin-exacerbated respiratory disease, aspirin exposure can also trigger an attack.
• Quiet-day sampling: a normal baseline sample can miss episodic mast-cell activation. A flare sample compared with your own baseline is usually more useful.
• Collection problems: a missed 24-hour collection, poor storage, or a random sample without urine-concentration adjustment can distort the reading.
• Other inflammatory sources: PGD2 is strongly tied to mast cells, but elevation is not specific for systemic mastocytosis. Angioedema, diffuse hives, and other inflammatory disorders can raise related signals.
• High basal tryptase from an inherited trait: in hereditary alpha-tryptasemia, blood tryptase runs high but this urine metabolite usually stays normal, which actually helps separate true mediator release from the inherited trait.